Derek Liu

Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy.

D. Schadendorf, J. Becker, S. Ugurel, 2020, The Journal of clinical investigation.

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene

D. Kufe, S. Kharbanda, Dongshu Chen, 2003, Oncogene.

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

A. Regev, J. Utikal, S. Haferkamp, 2020, Nature Medicine.

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade.

C. Paweletz, P. Hammerman, P. Lizotte, 2020, The Journal of clinical investigation.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

A. Regev, J. Utikal, S. Haferkamp, 2019, Nature Medicine.

MUC1 Oncoprotein Blocks Glycogen Synthase Kinase 3β–Mediated Phosphorylation and Degradation of β-Catenin

L. Yin, D. Kufe, S. Kharbanda, 2005 .

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.

L. Yin, D. Kufe, S. Kharbanda, 2005, Cancer research.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

A. Regev, J. Utikal, S. Haferkamp, 2019, Nature Medicine.